Search results
Showing 301 to 315 of 873 results for community guidance
In development Reference number: GID-TA11554 Expected publication date: TBC
Brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over [ID6448]
In development Reference number: GID-TA11564 Expected publication date: 08 July 2026
This guideline covers good practice for developing, authorising, using and updating patient group directions. It also offers advice on deciding whether a patient group direction is needed.
View recommendations for MPG2Show all sections
In development Reference number: GID-HTE10067 Expected publication date: 20 May 2026
Tell us what matters to you, your organisation or your community.
Tell us what matters to you, your organisation or your community.
Developmental follow-up of children and young people born preterm (NG72)
This guideline covers the developmental follow-up of babies, children and young people under 18 years who were born preterm (before 37+0 weeks of pregnancy). It explains the risk of different developmental problems and disorders, and specifies what extra assessments and support children born preterm might need during their growth and development.
Our associates help us to support high quality, safe, cost-effective prescribing and medicines optimisation.
COVID-19 rapid guideline: haematopoietic stem cell transplantation (NG164)
The purpose of this guideline is to maximise the safety of patients who need haemopoietic stem cell transplantation and make the best use of NHS resources, while protecting staff from infection.
Show all sections
This quality standard covers increasing the uptake of flu vaccination among people who are eligible. It describes high-quality care in priority areas for improvement.
In development Reference number: GID-HTE10065 Expected publication date: 02 April 2026
This guideline covers targeted interventions to prevent misuse of drugs, including illegal drugs, ‘legal highs’ and prescription-only medicines. It aims to prevent or delay harmful use of drugs in children, young people and adults who are most likely to start using drugs or who are already experimenting or using drugs occasionally.
In development Reference number: GID-TA11566 Expected publication date: TBC
This guideline covers assessing and reducing the risk of venous thromboembolism (VTE or blood clots, including deep vein thrombosis and pulmonary embolism) in people aged 16 and over in hospital. It aims to help healthcare professionals identify people most at risk and describes interventions that can be used to reduce the risk of VTE.
Clostridium difficile infection: risk with broad-spectrum antibiotics (ESMPB1)
Summary of the evidence on the risk of using broad-specturm antibiotics associated with clostridium difficile infection